LuciTuca — Tucatinib 150 mg, 60 pcs, Lucius

LuciTuca — Tucatinib Tablets 150 mg, 60 Tablets

Product code: 516

84930₴ 92574₴ -8% On order · from 10 days

Analogues

LuciTuca Tucaxen 150
1
Active ingredient
Dosage
150 mg
Dosage form Tablets
Tablets per pack 60

LuciTuca is a highly selective targeted antineoplastic agent belonging to the tyrosine kinase inhibitor class, indicated for the treatment of HER2-positive metastatic breast cancer and colorectal cancer. The active pharmaceutical ingredient is tucatinib at a strength of 150 mg supplied as film-coated oral tablets (Tucatinib Tablets 150 mg). The product is developed and manufactured by Lucius Pharmaceuticals.

Tucatinib is an oral, highly selective tyrosine kinase inhibitor of the HER2 receptor (human epidermal growth factor receptor 2). Unlike other HER2 inhibitors, tucatinib exhibits exceptional selectivity specifically for HER2 without prominent inhibition of EGFR (HER1), significantly reducing the incidence of cutaneous and gastrointestinal adverse effects. The drug is effectively utilized in combination with trastuzumab and capecitabine, including in patients with brain metastases, demonstrating outstanding blood-brain barrier penetration.

Supplied in a package containing 60 tablets of 150 mg. Intended exclusively for oral administration under the strict supervision of an oncologist.

Key Clinical Features and Advantages of LuciTuca 150 mg:

  • ✅ High HER2 Selectivity: Targeted blockade of HER2 receptors with minimal EGFR impact, reducing toxicity.
  • ✅ CNS Metastases Efficacy: Excellent blood-brain barrier penetration for intracranial lesion control.
  • ✅ Combination Therapy: Proven synergistic efficacy when combined with trastuzumab and capecitabine.
  • ✅ Convenient Form: 150 mg tablets taken twice daily.
  • ✅ Lucius Pharmaceuticals Standards: High-quality, accessible generic alternative to the originator product (Tukysa).

LuciTuca is supplied as film-coated tablets for oral administration.

Qualitative and Quantitative Composition per Tablet:

  • Active Ingredient: Tucatinib — 150 mg.
  • Excipients: Copovidone, crospovidone, sodium stearyl fumarate, colloidal anhydrous silica, microcrystalline cellulose. Coating: hypromellose, titanium dioxide, triacetin, iron oxide yellow.

Packaging and Presentation: Film-coated tablets, 150 mg strength. Each package contains 60 tablets along with prescribing information. Labeled with LuciTuca (Tucatinib Tablets 150 mg) and Lucius Pharmaceuticals corporate graphics.

Pharmacodynamics:
Tucatinib is a reversible tyrosine kinase inhibitor that selectively blocks HER2. HER2 inhibition suppresses receptor autophosphorylation, halts downstream signaling pathways (MAPK and PI3K/AKT), and induces apoptosis in HER2-overexpressing tumor cells. Due to its minimal impact on EGFR receptors, tucatinib less frequently causes severe diarrhea and rashes typical of non-selective inhibitors.

Pharmacokinetics:

  • Absorption: Following oral administration, tucatinib is rapidly absorbed; peak plasma concentration (Tmax) is achieved within approximately 1.5 to 2 hours. Food intake has no clinically significant effect on bioavailability.
  • Distribution: Human plasma protein binding is moderate (approx. 97%). The drug penetrates well into central nervous system tissues.
  • Metabolism: Extensively metabolized in the liver, primarily via CYP2C8 and to a lesser extent CYP3A4 enzymes of the cytochrome P450 system.
  • Elimination: Excreted predominantly via feces (approx. 86% as metabolites) and renally (approx. 4%). Terminal elimination half-life (T1/2) averages approximately 7.5 hours.

LuciTuca is indicated in adult patients for:

  • HER2-Positive Breast Cancer: In combination with trastuzumab and capecitabine for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens in the metastatic setting (including patients with brain metastases).
  • Colorectal Cancer: In combination with trastuzumab for the treatment of patients with HER2-positive metastatic colorectal cancer whose disease has progressed following chemotherapy.

LuciTuca is administered orally twice daily every day (morning and evening) continuously as part of combination therapy.

Dosing Regimen:
The recommended standard dose is 300 mg (two 150 mg tablets) twice daily (total daily dose of 600 mg) administered continuously until disease progression or unacceptable toxicity occurs.

Administration Guidelines:
Tablets should be taken regardless of food intake, approximately every 12 hours, with water. Tablets must be swallowed whole; do not break, crush, or chew. If a dose is missed or vomiting occurs after ingestion, do not take an extra dose — take the next tablet at the scheduled time.

Administration of LuciTuca is contraindicated in:

  • Hypersensitivity: Known hypersensitivity to tucatinib or any excipient.
  • Pregnancy and Lactation: Strictly contraindicated in pregnant or breastfeeding women.
  • Pediatric Population: Safety and efficacy in patients under 18 years have not been established.
  • Severe Hepatic Impairment: Pronounced liver dysfunction (Child-Pugh Class C).

Tucatinib is metabolized via CYP2C8 and CYP3A4 enzymes and acts as a substrate and inhibitor of certain transporters:

  • Strong CYP2C8 or CYP3A4 Inducers (rifampicin, carbamazepine, phenytoin, St. John's Wort): Significantly decrease tucatinib plasma concentrations and reduce efficacy (avoid concurrent use).
  • Strong CYP2C8 Inhibitors (gemfibrozil): May elevate tucatinib exposure and toxicity risks (avoid concurrent use).
  • P-gp and CYP3A4 Substrates: Tucatinib may increase concentrations of co-administered drugs metabolized via these pathways (e.g., midazolam, irinotecan).

Pregnancy:
LuciTuca is contraindicated during pregnancy. Based on its mechanism of action, tucatinib may cause fetal harm and embryotoxicity. Females of reproductive potential and male partners must utilize effective reliable contraception during treatment and for at least 1 week following the final dose.

Lactation:
Excretion of tucatinib into human breast milk is unstudied. Breastfeeding must be discontinued during treatment and for 1 week post-therapy.

The most frequent and clinically significant adverse reactions include (when administered with trastuzumab and capecitabine):

  • Gastrointestinal Tract: Diarrhea (a primary adverse effect requiring prompt anti-diarrheal therapy), nausea, vomiting, stomatitis, abdominal pain.
  • Hepatic Abnormalities: Elevations in liver transaminases (ALT, AST) and bilirubin levels (routine laboratory monitoring required).
  • General Disorders: Fatigue, asthenia, headache, rash, palmar-plantar erythrodysesthesia.
  • Laboratory Abnormalities: Anemia, decreased white blood cells and platelets.

Symptoms:
Specific acute overdose symptoms of tucatinib are unestablished. Anticipated manifestations include exacerbated adverse reactions (severe diarrhea, nausea, elevated liver transaminases).

Treatment:
No specific antidote exists. In case of overdose, withhold treatment and initiate supportive and symptomatic care under rigorous medical observation.

Storage Requirements for LuciTuca 150 mg:

  • 🌡️ Temperature Range: Store in original packaging in a dry place protected from light at temperatures below 30 °C.
  • 👶 Safety Precautions: Keep strictly out of reach of children (cytotoxic antineoplastic agent).
  • ⏳ Shelf Life: Stated on carton and blister pack. Don't use past expiration date. Prescription-only oncology medicine.

To verify authenticity of genuine LuciTuca 150 mg manufactured by Lucius Pharmaceuticals, inspect the following security and visual features:

  • ✅ Security Hologram & Scratch Code: Outer carton features an official Lucius Pharmaceuticals anti-counterfeit holographic seal with a scratch-off verification code for online validation via the manufacturer's official portal.
  • ✅ Corporate Branding: High-resolution printing displaying Lucius Pharmaceuticals graphics, Tucatinib Tablets 150 mg, and 60 Tablets count.
  • ✅ Factory Markings: Clearly printed Batch No., Mfg. Date, and Exp. Date matching across outer packaging and internal blister packs.
  • ✅ Prescribing Information: Includes an official product leaflet inside the outer carton.
On order · from 10 days
100% original product
Delivery across Ukraine
1

Notice. The information on this page is for reference only and does not replace medical consultation. Always consult a healthcare professional and read the manufacturer's instructions before using any medicine. Self-medication may be dangerous. Information updated: 17.11.2026

Customer reviews

No reviews yet

Your review can be the first!

Contact us

Choose a convenient way to contact

We work daily from 9:00 to 20:00